Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Drugmakers want more clarity from the Trump administration on the potential pharmaceutical tariffs, which some companies warn ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to US$1.3 billion to boost its pipeline beyond its blockbuster weight-loss and diabetes drugs.

The NHS Mounjaro rollout begins next week across the UK, and here are the side effects users need to be aware of ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver.

Surgery Partners rejects Bain Capital's acquisition bid, citing greater long-term value as a public company with strong ...

A well-crafted letter of intent is the foundation of a successful acquisition, setting the tone for negotiations and ...